Identifying Genetic Risk Factors for Diabetic Macular Edema and the Response to Treatment.

Rajya L Gurung, Liesel M FitzGerald, Bennet J McComish, Nitin Verma, Kathryn P Burdon

Journal: Journal of diabetes research 2021;2020():5016916

PMID: 33274237

Free Full Text on PubMed Central View on PubMed

Abstract

Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus (DM). DR is complex and the term encompasses several clinical subtypes of diabetic eye disease, including diabetic macular edema (DME), the most frequent cause of central vision loss in DR patients. Both genetic and environmental factors contribute to the pathophysiology of DR and its subtypes. While numerous studies have identified several susceptibility genes for DR, few have investigated the impact of genetics on DME susceptibility. This review will focus on the current literature surrounding genetic risk factors associated with DME. We will also highlight the small number of studies investigating the genetics of response to antivascular endothelial growth factor (anti-VEGF) injection, which is used to treat DME.

Address: Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.; School of Medicine, University of Tasmania, Hobart, TAS, Australia.

DOI: 10.1155/2020/5016916

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/diabeticeyeproblems.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-AKR1B1-1

MeSH Terms: Aldehyde Reductase, Angiogenesis Inhibitors, Apolipoproteins E, Bevacizumab, Diabetic Retinopathy, Erythropoietin, Eye Proteins, Genetic Predisposition to Disease, Humans, Macular Edema, MicroRNAs, Nerve Growth Factors, Nitric Oxide Synthase, Ranibizumab, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Serpins, Superoxide Dismutase, Treatment Outcome, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor C